Canaccord analyst William Plovanic lowered the firm’s price target on Merit Medical to $86 from $88 and keeps a Hold rating on the shares. The firm said Q2 was highlighted by strength in Cardiovascular business segments and accretive acquisitions and this marks the second quarter in a row where the company beat revenue and EPS estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MMSI: